A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 3, 2013, Pages 1040-1050

  Annamalai, Anand K ^a   Webb, Alison ^a   Kandasamy, Narayanan ^a   Elkhawad, Maysoon ^a   Moir, Samantha ^c   Khan, Fakhar ^a   Maki Petaja, Kaisa ^a   Gayton, Emma L ^a   Strey, Christopher H ^a   O'Toole, Samuel ^a   Ariyaratnam, Shaumya ^a   Halsall, David J ^a   Chaudhry, Afzal N ^a   Berman, Laurence ^b   Scoffings, Daniel J ^b   Antoun, Nagui M ^b   Dutka, David P ^a   Wilkinson, Ian B ^a   Shneerson, John M ^c   Pickard, John D ^a   Simpson, Helen L ^a   Gurnell, Mark ^a   more..

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c PAPWORTH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; GROWTH HORMONE; SOMATOMEDIN C;

ACROMEGALY; ADULT; AGED; APNEA HYPOPNEA INDEX; ARTERIAL STIFFNESS; ARTICLE; BLOOD FLOW; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR PARAMETERS; CLINICAL ARTICLE; COHORT ANALYSIS; DIASTOLIC BLOOD PRESSURE; FEMALE; HEART LEFT VENTRICLE MASS; HUMAN; HYPOPHYSIS TUMOR; MALE; METABOLIC PARAMETERS; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULSE WAVE; RADIOLOGICAL PARAMETERS; REFERENCE VALUE; RESPIRATORY TRACT DISEASE; SCORING SYSTEM; SLEEP DISORDER; SLEEP PARAMETERS; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME; VASCULAR ENDOTHELIUM; VASODILATATION;

ACROMEGALY; ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMAN GROWTH HORMONE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; PREOPERATIVE CARE; PROSPECTIVE STUDIES; RECEPTORS, SOMATOSTATIN; SLEEP APNEA SYNDROMES; SOMATOSTATIN; TREATMENT OUTCOME; VASCULAR STIFFNESS; YOUNG ADULT;

EID: 84874860258     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-3072     Document Type: Article

References (60)

1. Melmed S. Acromegaly. N Engl J Med. 2006;355:2558-2573. (Pubitemid 44917504)
2. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev. 2004;25:102-152. (Pubitemid 38269977)
3. Melmed S, Colao A, Barkan A, et al. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab. 2009;94:1509-1517.
4. Lissett CA, Peacey SR, Laing I, Tetlow L, Davis JR, Shalet SM. The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenoma. Clin Endocrinol (Oxf). 1998;49:653-657. (Pubitemid 28529765)
5. Ahmed S, Elsheikh M, Stratton IM, Page RC, Adams CB, Wass JA. Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience. Clin Endocrinol (Oxf). 1999;50:561-567. (Pubitemid 29236331)
6. De P, Rees DA, Davies N, et al. Transsphenoidal surgery for acromegaly in Wales: results based on stringent criteria of remission. J Clin Endocrinol Metab. 2003;88:3567-3572. (Pubitemid 37034496)
7. Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure.' Eur J Endocrinol. 2005;152:379-387. (Pubitemid 40439490)
8. Kaltsas GA, Isidori AM, Florakis D, et al. Predictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity. J Clin Endocrinol Metab. 2001;86:1645-1652. (Pubitemid 32374917)
9. Shimon I, Cohen ZR, Ram Z, Hadani M. Transsphenoidal surgery for acromegaly: endocrinological follow-up of 98 patients. Neurosurgery. 2001;48:1239-1243.
10. Beauregard C, Truong U, Hardy J, Serri O. Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol (Oxf). 2003;58:86-91. (Pubitemid 36098853)
11. Ludecke DK, Abe T. Transsphenoidal microsurgery for newly diagnosed acromegaly: a personal view after more than 1,000 operations. Neuroendocrinology. 2006;83:230-239. (Pubitemid 44578877)
12. Petrossians P, Borges-Martins L, Espinoza C, et al. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur J Endocrinol. 2005;152:61-66. (Pubitemid 40185454)
13. Colao A, Attanasio R, Pivonello R, et al. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. J Clin Endocrinol Metab. 2006;91:85-92. (Pubitemid 43069122)
14. Karavitaki N, Turner HE, Adams CB, et al. Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide. Clin Endocrinol (Oxf). 2008;68:970-975. (Pubitemid 351703951)
15. Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP. Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab. 2008;93:61-67.
16. Giustina A, Chanson P, Bronstein MD, et al. Aconsensus on criteria for cure of acromegaly. J Clin Endocrinol Metab. 2010;95:3141-3148.
17. Colao A, Auriemma RS, Galdiero M, Lombardi G, Pivonello R. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. J Clin Endocrinol Metab. 2009;94:3746-3756.
18. Colao A, Ferone D, Cappabianca P, et al. Effect of octreotide pretreatment on surgical outcome in acromegaly. J Clin Endocrinol Metab. 1997;82:3308-3314. (Pubitemid 27419077)
19. Losa M, Mortini P, Urbaz L, Ribotto P, Castrignanó T, Giovanelli M. Presurgical treatment with somatostatin analogs in patients with acromegaly: effects on the remission and complication rates. J Neurosurg. 2006;104:899-906. (Pubitemid 43824739)
20. Plöckinger U, Quabbe HJ. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study. Acta Neurochir. 2005;147:485-493. (Pubitemid 40603128)
21. Abe T, Ludecke DK. Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre. Eur J Endocrinol. 2001;145:137-145. (Pubitemid 32707599)
22. Barkan AL, Lloyd RV, Chandler WF, et al. Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. J Clin Endocrinol Metab. 1988;67:1040-1048.
23. Stevenaert A, Beckers A. Presurgical octreotide treatment in acromegaly. Acta Endocrinol (Copenh). 1993;129(suppl 1):18-20. (Pubitemid 23236056)
24. Carlsen SM, Lund-Johansen M, Schreiner T, et al. Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. J Clin Endocrinol Metab. 2008;93: 2984-2990.
25. Amato G, Mazziotti G, Rotondi M, et al. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol (Oxf). 2002;56:65-71. (Pubitemid 34107323)
26. Bevan JS. The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab. 2005;90:1856-1863. (Pubitemid 40464061)
27. Bevan JS, Atkin SL, Atkinson AB, et al. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab. 2002;87:4554-4563.
28. Colao A, Ferone D, Marzullo P, et al. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab. 2001;86: 2779-2786. (Pubitemid 32545739)
29. Melmed S, Sternberg R, Cook D, et al. Acritical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab. 2005;90:4405-4410. (Pubitemid 41058228)
30. Mazziotti G, Giustina A. Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review. Pituitary. 2010;13:60-67.
31. Lim MJ, Barkan AL, Buda AJ. Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion. Ann Intern Med. 1992;117:719-726.
32. Chanson P, Timsit J, Masquet C, Warnet A, et al. Cardiovascular effects of the somatostatin analog octreotide in acromegaly. Ann Intern Med. 1990;113:921-925.
33. Smith JC, Lane H, Davies N, et al. The effects of depot long-acting somatostatin analog on central aortic pressure and arterial stiffness in acromegaly. J Clin Endocrinol Metab. 2003;88:2556-2561. (Pubitemid 36724423)
34. Paisley AN, Banerjee M, Rezai M, et al. Changes in arterial stiffness but not carotid intimal thickness in acromegaly. J Clin Endocrinol Metab. 2011;96:1486-1492.
35. Ip MS, Tan KC, Peh WC, Lam KS. Effect of Sandostatin LAR on sleep apnoea in acromegaly: correlation with computerized tomographic cephalometry and hormonal activity. Clin Endocrinol (Oxf). 2001;55:477-483. (Pubitemid 32955485)
36. Tolis G, Angelopoulos NG, Katounda E, et al. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs. Neuroendocrinology. 2006;83:249-257. (Pubitemid 44578879)
37. Herrmann BL, Wessendorf TE, Ajaj W, Kahlke S, Teschler H, Mann K. Effects of octreotide on sleep apnoea and tongue volume (magnetic resonance imaging) in patients with acromegaly. Eur J Endocrinol. 2004;151:309-315. (Pubitemid 39307317)
38. Carlsen SM, Svartberg J, Schreiner T, et al. Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure. Clin Endocrinol (Oxf). 2011;74:736-743.
39. Giustina A, Mazziotti G, Torri V, Spinello M, Floriani I, Melmed S. Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS One. 2012;7:e36411.
40. Attal P, Chanson P. Endocrine aspects of obstructive sleep apnea. J Clin Endocrinol Metab. 2010;95:483-495.
41. Rosenow F, Reuter S, Deuss U, et al. Sleep apnoea in treated acromegaly: relative frequency and predisposing factors. Clin Endocrinol (Oxf). 1996;45:563-569. (Pubitemid 26411357)
42. Grunstein RR, Ho KK, Sullivan CE. Effect of octreotide, a soma tostatin analog, on sleep apnea in patients with acromegaly. Ann Intern Med. 1994;121:478-483.
43. Davi MV, Carbonare LD, Giustina A, et al. Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease. Eur J Endocrinol. 2008;159: 533-540.
44. Grunstein RR, Ho KY, Sullivan CE. Sleep apnea in acromegaly. Ann Intern Med. 1991;115:527-532.
45. Ryan PJ, Hilton MF, Boldy DA, et al. Validation of British Thoracic Society guidelines for the diagnosis of the sleep apnoea/hypopnoea syndrome: can polysomnography be avoided? Thorax. 1995;50: 972-975.
46. Dostálová S, Sonka K, Smahel Z, Weiss V, Marek J. Cephalometric assessment of cranial abnormalities in patients with acromegaly. J Craniomaxillofac Surg. 2003;31:80-87. (Pubitemid 36367804)
47. Peppard PE, Young T, Palta M, Dempsey J, Skatrud J. Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA. 2000;284:3015-3021. (Pubitemid 32014738)
48. O'Sullivan AJ, Kelly JJ, Hoffman DM, Freund J, Ho KK. Body composition and energy expenditure in acromegaly. J Clin Endocrinol Metab. 1994;78:381-386. (Pubitemid 24061757)
49. Kaji H, Sugimoto T, Nakaoka D, Okimura Y, Abe H, Chihara K. Bone metabolism and body composition in Japanese patients with active acromegaly. Clin Endocrinol (Oxf). 2001;55:175-181. (Pubitemid 32868581)
50. Hansen TB, Gram J, Bjerre P, Hagen C, Bollerslev J. Body composition in active acromegaly during treatment with octreotide: a double-blind, placebo-controlled cross-over study. Clin Endocrinol (Oxf). 1994;41:323-329. (Pubitemid 24278326)
51. Sucunza N, Barahona MJ, Resmini E, et al. Gender dimorphism in body composition abnormalities in acromegaly: males are more affected than females. Eur J Endocrinol. 2008;159:773-779.
52. Colao A, Pivonello R, Grasso LF, et al. Determinants of cardiac disease in newly diagnosed patients with acromegaly: results of a 10 year survey study. Eur J Endocrinol. 2011;165:713-721.
53. Colao A, Vitale G, Pivonello R, Ciccarelli A, DiSomma C, Lombardi G. The heart: an end-organ of GH action. Eur J Endocrinol 2004;151(suppl 1):S93-S101. (Pubitemid 39276355)
54. Saccà L, Cittadini A, Fazio S. Growth hormone and the heart. Endocr Rev. 1994;15:555-573. (Pubitemid 24328207)
55. Brevetti G, Marzullo P, Silvestro A, et al. Early vascular alterations in acromegaly. J Clin Endocrinol Metab. 2002;87:3174-3179. (Pubitemid 34816361)
56. Laurent S, Cockcroft J, Van Bortel L, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006;27:2588-2605. (Pubitemid 44627304)
57. Sakai H, Tsuchiya K, Nakayama C, et al. Improvement of endothelial dysfunction in acromegaly after transsphenoidal surgery. Endocr J. 2008;55:853-859.
58. Badway AC, Blake AD. Somatostatin: a hormone for the heart? Curr Vasc Pharmacol. 2005;3:125-131. (Pubitemid 40601582)
59. Smith WH, Nair RU, Adamson D, Kearney MT, Ball SG, Balmforth AJ. Somatostatin receptor subtype expression in the human heart: differential expression by myocytes and fibroblasts. J Endocrinol. 2005;187:379-386. (Pubitemid 43020259)
60. Colao A, Marzullo P, Cuocolo A, et al. Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide. Clin Endocrinol (Oxf). 2003;58:169-176. (Pubitemid 36194271)